SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs.

Jason joins DeepQure from SoniVie, an Israeli company developing catheter-based intravascular ultrasound renal denervation (RDN) treatment that was acquired by Boston Scientific for $540 million in March 2025. At SoniVie, he led the global clinical development strategy and clinical operations activities at the company. Jason oversaw the completion of enrollment for their Early Feasibility Study (EFS) IDE and developed and implemented the currently ongoing pivotal IDE.

With over 20 years of experience in clinical and regulatory affairs, Jason has successfully

See Full Page